Ratings Beximco Pharmaceuticals Limited

Equities

End-of-day quote Dhaka S.E. Other stock markets 06:00:00 2024-04-24 pm EDT			5-day change	1st Jan Change
116.1 ^BDT	-0.43%		-1.36%	-20.59%

Mar. 04	Beximco names Iqbal Ahmed as managing director	AN
Jan. 30	Beximco Pharmaceuticals to strengthen portfolio as interim profit up	AN

On the basis of various fundamental qualitative criteria, the company appears to be particularly poorly ranked from a medium and long-term investment perspective.

Its low valuation, with P/E ratio at 9.44 and 7.69 for the ongoing fiscal year and 2025 respectively, makes the stock pretty attractive with regard to earnings multiples.
The average target price set by analysts covering the stock is above current prices and offers a tremendous appreciation potential.
Analysts' price targets are all relatively close, reflecting good visibility on the company's valuation.

The overall consensus opinion of analysts has deteriorated sharply over the past four months.

	1st Jan change	Capi.	ESG Refinitiv
BEXIMCO PHARMACEUTICALS LIMITED	-20.59%	472M	-
ELI LILLY AND COMPANY	+25.83%	661B	C+
NOVO NORDISK A/S	+27.00%	566B	B
JOHNSON & JOHNSON	-6.76%	352B	C+
MERCK & CO., INC.	+20.34%	332B	B-
ABBVIE INC.	+3.00%	283B	C+
ASTRAZENECA PLC	+13.09%	231B	B+
NOVARTIS AG	+5.46%	200B	B-
ROCHE HOLDING AG	-9.61%	195B	A+
AMGEN INC.	-6.26%	145B	C+

Investor Rating

Trading Rating

ESG Refinitiv

Sales growth

Earnings Growth

EBITDA / Sales

Profitability

Finances

P/E ratio

EV / Sales

Price to Book

Price to Free Cash Flow

Yield

1 year Revenue revision

4 months Revenue revision

7 days Revenue revision

1 year EPS revision

4 months EPS revision

Analyst Opinion

Potential Price Target

4m Target Price Revision

4m Revision of opinion

12m Revision of opinion

Analyst Coverage

Divergence of Estimates

Divergence of analysts' opinions

Divergence of Target Price

Earnings quality